Skip to main content
Ingredients/Probiotic/Lactobacillus Gasseri SBT2055

Lactobacillus Gasseri SBT2055.

Strength pending.The research strength is not set yet.

Lactobacillus Gasseri SBT2055 supplementation for targeted health support. Appears to reduce fat absorption in the gut and may influence metabolism through gut-fat axis signaling. Clinical trials show reduced abdominal fat, BMI, and waist circumference.

1,000,000,000 to 10,000,000,000 CFUDaily amount225Studies read

Reviewed March 2026

LGProbiotic
Lactobacillus Gasseri SBT2055IngredientMD
Category
Probiotic

What Lactobacillus Gasseri SBT2055 is, and what it does.

Does it work
One of the few probiotics with weight-related clinical data. The effects are modest but real. Worth adding to a comprehensive weight management approach.
How much to take
100 million to 10 billion CFU daily. Japanese studies used fermented milk providing around 200 million cells.
Time to feel it
Trials ran twelve weeks before abdominal measurements moved, so this is tracked with a tape measure across months rather than noticed in a week.
The first dose
Day one is quiet. Cells are arriving and beginning to ferment, and a little extra gas is common through the first few days before it settles.
With regular use
Studies show 4-8% reduction in abdominal fat over 12 weeks. Modest but meaningful. Requires consistent daily use.
How well tolerated
Excellent. Standard probiotic safety with specific research on this strain.
How it feels
Subtle. You measure changes in waist size and body composition, not dramatic feeling changes.
The overlooked benefit
It has been reclassified as Lactobacillus paragasseri, so the same strain appears under two species names and a search on one name misses part of its record.

1,000,000,000 to 10,000,000,000 CFU a day is where Lactobacillus Gasseri SBT2055 works.

How much to take a dayMedium confidence
1,000,000,000 to 10,000,000,000 CFU
Daily maintenanceThe everyday amount, and where most daily supplements sit. This is the one you take month after month.
50,000,000,000 CFUClinical territory. Trials run high on purpose, for a set number of weeks, against one measured outcome. Impressive to hit, and not what a daily product is for.
Above 100,000,000,000 CFUPast what the research covers. More capsules rather than more effect.
MORE EFFECT ↑010,000,000,000 CFU50,000,000,000 CFU plateauDAILY DOSE →
The shaded band is where the dosing trials landed.

Source: ISAPP consensus statement 2019 + Ford 2014 meta-analysis

The proof, claim by claim.

These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.

Lactobacillus Gasseri SBT2055 has emerging evidence. Based on 225+ studies.

  • Reduces abdominal fatMultiple RCTs with CT scan measurements
  • Decreases BMI and waist circumferenceConsistent findings across studies
  • May reduce fat absorptionMechanism studies support
  • Well tolerated in regular useClinical safety data
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AI225 studies readLabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AI225 studies readLabs test. IngredientMD verifies.

Questions people ask about Lactobacillus Gasseri SBT2055.

Does this actually help lose weight?
It helps lose abdominal fat specifically. Studies show 4-8% reduction over 12 weeks. Modest but statistically significant.
How does a probiotic affect fat?
May reduce dietary fat absorption and influence hormones that regulate fat storage. The exact mechanism is still being studied.
Is this better than diet and exercise?
No. Use alongside diet and exercise. It's a modest addition, not a replacement for lifestyle changes.
Why Japanese research?
SBT2055 was isolated in Japan by Snow Brand (now Megmilk). Most research is from Japan but published in international journals.
Are the effects permanent?
Benefits likely require ongoing use. Stopping may result in return to baseline, similar to stopping any weight management strategy.
Can I get it in the US?
Available in supplements. Not in the original Japanese fermented milk products, but capsule forms are marketed internationally.
Pairs well with23 on file

Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.

Chicory fructans are a selective carbon source for lactobacilli, supporting the delivered strain as it transits. Pairing strain with substrate is standard synbiotic construction.

Lactobacilli cleave galactooligosaccharides with the beta-galactosidase they already carry, so GOS is directly usable substrate. The fermentation acids that follow lower colonic pH.

Resistant starch escapes small intestinal digestion and ferments in the distal colon, extending substrate supply past the point where short fructans are exhausted. It broadens the fermentation window for a delivered strain.

Lactate and acetate from lactobacilli are taken up by bifidobacteria and butyrate producers, so the genera reinforce each other. Multi-genus blends are built on this.

Butyrate producers consume the lactate that lactic acid bacteria release, converting it to the short-chain fatty acid colonocytes use as fuel. The pair covers both halves of that conversion.

Lactobacillus Gasseri SBT2055 + LactoferrinIron sequestration favours lactic acid bacteria

By binding free luminal iron, lactoferrin disadvantages iron-hungry genera while lactobacilli, which need very little iron, are relatively favoured. This is why lactoferrin appears as a co-agent in strain formulas.

A yeast tolerates the acidic environment lactobacilli create and does not compete for the same carbon sources or adhesion sites. Combining the two in one formula is long-standing practice.

Charcoal adsorbs luminal organics without selectivity, including fermentable substrate and bacterial metabolites. Keep several hours between it and any live culture.

Silver ions act on membranes and thiol enzymes across bacterial genera, lactic acid bacteria included. Concurrent dosing works against the delivered strain.

Fructooligosaccharides pass the small intestine largely intact and are fermented by lactobacilli and bifidobacteria in the colon. Supplying a fermentable substrate alongside a live strain is the standard synbiotic construction and is why so many products carry both. The substrate relationship is established; how much it changes any measured outcome for this particular strain is not.

Psyllium is a viscous arabinoxylan gel that is only partly fermented, so it acts on transit time and stool form more than it acts as a feedstock for a single strain. Slower, more hydrated transit changes the environment a delivered strain lands in. The pairing is common and physiologically coherent, and it has not been measured with this strain.

Hydrolysing guar gum lowers its viscosity while keeping the galactomannan backbone fermentable, which is exactly the profile used when a formulator wants a prebiotic without a thickening effect. Colonic bacteria including lactobacilli ferment it to short-chain fatty acids. The substrate chemistry is settled; the strain-specific effect is not.

Lactobacillus Gasseri SBT2055 + Guar Gumestablished microbial nutrition

Native guar gum is a fermentable galactomannan that reaches the colon and feeds resident fermenters. It is more viscous than its hydrolysed form, so it also slows gastric emptying. Pairing it with a live strain gives the strain a substrate; the viscosity is the trade-off a formulator has to design around.

Lactobacillus Gasseri SBT2055 + Pectinestablished microbial nutrition

Pectin is a fermentable plant polysaccharide that colonic bacteria break down to short-chain fatty acids, and its gel structure can shelter cells during gastric transit. Both roles are established for pectin generally. Neither has been quantified with this strain.

Oat beta-glucan is a viscous, fermentable fibre that resident colonic bacteria use as a carbon source. Its viscosity also slows the delivery of the whole meal. A live strain co-delivered with it arrives alongside its own substrate, which is the logic of the pairing rather than a measured result.

Lactobacillus Gasseri SBT2055 + Lactobacillus Acidophilusformulation practice in multi-strain products

Multi-strain blends put several lactobacilli in one capsule on the reasoning that they occupy overlapping niches without displacing each other. That is a formulation convention supported by manufacturing experience rather than by co-administration trials for this pair. Strain-level effects do not add up predictably, so a blend is not the sum of what each strain showed alone.

Lactobacillus Gasseri SBT2055 + Lactobacillus Plantarumformulation practice in multi-strain products

L. plantarum is one of the most frequently co-formulated species in lactobacillus blends because it tolerates a wide pH range during processing. Combining it with this strain is a manufacturing and coverage decision. It does not transfer either strain's individual findings to the blend.

Bifidobacteria sit in the colon while lactobacilli are more prominent in the small intestine, so the two genera are combined to cover both compartments. The ecological rationale is well described. Any joint effect on a measured outcome would have to be shown for the specific pair, and it has not been.

Lactobacilli including this species carry beta-galactosidase activity, the same reaction supplemental lactase performs, which is part of why fermented milk carries less lactose than the milk it came from. Co-delivering the enzyme and a lactose-fermenting strain addresses the same sugar by two routes. The enzymology is settled; the combination has not been measured.

Dietary calcium forms insoluble soaps with free fatty acids and binds bile acids in the intestinal lumen, which increases the fat that leaves in the stool. That is the same faecal-fat compartment the strain-level claims for this organism point at, so the two overlap and a study of one against a high-calcium background is hard to interpret. Calcium's effect on faecal fat is established; the interaction with this strain is inference.

Lactobacillus Gasseri SBT2055 + Oregano Oilestablished antimicrobial pharmacology

Carvacrol and thymol are broad antimicrobials that disrupt bacterial membranes without distinguishing a supplemented strain from a resident one. Taken in the same dose window as a live culture, they can reduce the number of viable cells that survive to the colon. Separating the two by several hours is the usual formulation answer. The antimicrobial activity is established; the size of the loss is not quantified.

Lactobacillus Gasseri SBT2055 + Berberineestablished antimicrobial pharmacology

Berberine has direct antibacterial activity and measurably shifts gut community composition. A live strain taken at the same time is exposed to that activity. This is a timing consideration rather than a reason to avoid either, and it rests on berberine's known antimicrobial profile rather than on a study of the pair.

Lactobacillus Gasseri SBT2055 + Aged Garlic Extractestablished antimicrobial pharmacology

Garlic organosulfur compounds inhibit a wide range of bacteria in culture, including lactobacilli. Aged preparations carry less allicin than fresh garlic, so the effect is likely smaller. The direction is grounded in the chemistry; nothing measures what happens to this strain's viable count in the presence of garlic in a human gut.

Who should be cautious

Nothing specific on file for Lactobacillus Gasseri SBT2055. Match the label to the daily amount above, and tell your doctor what you take.

Not medical advice. Show the label to your pharmacist.

What Lactobacillus Gasseri SBT2055 actually does.

Established

This strain has been reclassified as Lactobacillus paragasseri, so the same organism shows up in the literature under two species names. Search only one and you'll miss part of its record.

Established

Lactobacilli ferment lactose and other sugars into lactate, which lowers the local pH. That acidification is the classic way lactic acid bacteria make an environment less hospitable to organisms that can't handle acid.

Established

Bile salt hydrolase activity, which shows up strain by strain across lactobacilli, unhooks bile acids in the small intestine and changes how efficiently fat is emulsified and reabsorbed. That's the accepted mechanistic route by which a gut strain can alter fat in the stool.

Established

Probiotic effects are strain-specific: results measured on one strain don't transfer to another strain of the same species. A label naming only the species tells you less than one carrying the strain designation.

Grown by microbes, 6 steps on record

Where Lactobacillus Gasseri SBT2055 comes from.

The bacteria are grown in a tank from one carefully kept starter culture, spun out of the liquid, mixed with sugars that protect them, then freeze-dried into a powder. The other route skips the drying and sells them alive in a fermented milk drink, which is how they were first studied.

Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.

Starts as
Seed culture of the deposited strain

A frozen or lyophilised master seed of the specific strain, propagated through working seed stages so every batch traces back to one deposit rather than to a fresh isolate.

Converted by
Controlled batch fermentation

Growth in a milk-based or chemically defined medium with pH held by base addition and temperature held near the strain's optimum, harvested in late exponential phase when viability is highest.

Extracted by
Cell harvest

Cells are separated from spent medium by centrifugation or membrane filtration and washed to remove residual medium components.

Purified by
Concentration and cryoprotection

The cell paste is concentrated and blended with cryoprotectants such as sucrose, trehalose or a milk-solids base, which is what determines how many cells survive drying.

Standardised to
Count assay

Viable count is measured by plate count or flow cytometry and the dried powder is diluted with carrier to the declared figure, with a stability overage set against the shelf-life claim.

Ends up as
Freeze-dried powder or fermented milk

Lyophilisation gives the shelf-stable powder for capsules and sachets. The alternative route skips drying entirely and ships live cells in a refrigerated fermented milk, which is the format the original research on this strain used.

Labels rarely say whether the declared count is measured at manufacture or guaranteed to the end of shelf life, and they seldom name the cryoprotectant matrix, which is a large part of what determines survival through the gut.

The forms it comes in.

Lyophilised cells, CFU declaredDried whole cells with a cryoprotectant and a carrier, blended to a declared colony-forming-unit countFits Daily use where a stated count and a long shelf life matterTrade-off Some of the count is lost to gastric acid unless the capsule or matrix protects it, and the declared figure depends on whether it is stated at manufacture or at expiry
Live culture in a fermented dairy baseCells growing in and delivered by a fermented milk matrix, alongside milk protein, fat and the organic acids of fermentationFits Reproducing the delivery format used in the original research on this strainTrade-off Refrigerated, short shelf life, and the dairy matrix brings its own nutrients and its own lactose considerations, so the strain is not the only variable
Acid-resistant capsule shellSame lyophilised cells inside a shell that stays intact at gastric pH and opens further downFits Formulators who want more of the declared count to reach the intestineTrade-off Larger unit, added excipients, and the release point depends on transit conditions that vary between people
Synbiotic stick packCells blended with a fermentable oligosaccharide acting as both bulking agent and substrateFits Mixing into a drink or food, and for combining strain and substrate in one unitTrade-off The powder is exposed to moisture on opening, and the added fibre load can cause gas while the microbiota adjustsActive and formulation aid
What the strongest studies found

The essence, in one line each.

  1. Pooled trials in adults found probiotic supplementation was followed by small reductions in body weight, body mass index and waist circumference.Meta-analysis. Perna et al., 2021 (Nutrients). PMID 33669580
  2. In adults with higher than ideal blood cholesterol, a 12-week Lactobacillus supplement was followed by lower total and LDL cholesterol than placebo, with no tolerability problems recorded.Randomised trial. Khongrum et al., 2023 (Nutrients). PMID 36771367
  3. In animals, Lactobacillus paragasseri SBT2055, the current name for this strain, was reported to lower markers of insulin resistance and liver fat alongside reduced oxidative stress markers; these are biochemical markers in animals, not human outcomes.Animal study. Kim et al., 2025 (Beneficial Microbes). PMID 40716757
  4. A systematic review and meta-analysis of Lactobacillus probiotics in adults with excess body weight and no comorbid condition reported small pooled changes in anthropometric measures across strains; the pooling is at genus level and does not isolate this strain.Meta-analysis. Lele et al., 2025 (Narra Journal). PMID 40951500
  5. A systematic review of probiotics and synbiotics in people with overweight or excess body weight found the reported effects on weight measures inconsistent between strains and study designs; this strain is named inside the review rather than analysed on its own.Systematic review. Alvarez-Arrano et al., 2021 (Nutrients). PMID 34684633
  6. A review of Lactobacillus species as a targeted microbiome strategy in adults with high blood sugar summarises proposed mechanisms and notes that effects are strain-specific rather than a property of the genus.Narrative review. Cheah et al., 2026 (Current Nutrition Reports). PMID 41779301
  7. In a randomised single-blind placebo-controlled study, supplementation with Bifidobacterium and Lactobacillus strains did not produce a detectable difference in weight loss versus placebo; a failure to detect a difference, and the strains tested were not this one.Randomised trial. Czajeczny et al., 2021 (Eating and Weight Disorders). PMID 32797375
  8. A randomised double-blind trial of Lactobacillus plantarum K50 in Korean adults with excess body weight reported changes in blood lipid markers; markers rather than outcomes, and a different strain from this one.Randomised trial. Sohn et al., 2021 (Frontiers in Endocrinology). PMID 35126309
  9. A randomised controlled trial of Lactobacillus casei in postpartum women reported changes in low mood scores; a different species from this ingredient, included here only as context for how strain-specific probiotic findings are.Randomised trial. Abdollahpour et al., 2025 (BMC Psychiatry). PMID 41318456
  10. Several probiotic Lactobacillus strains inhibited growth of the oral bacterium Porphyromonas gingivalis in culture, illustrating that inhibition of a competing organism is strain-dependent.In vitro study. Kamianowski et al., 2026 (Probiotics and Antimicrobial Proteins). PMID 40736667

These are the studies our verdict leans on, chosen from the 248 we read for Lactobacillus Gasseri SBT2055. The full linked list is below.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.

On the shelf

What Lactobacillus Gasseri SBT2055 comes in.

Products in our catalog that carry it, read the same way every product here is read.